Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is a single arm, open-label trial studying the combination of PD-1/PD-L1 Inhibitor
(e.g.pembrolizumab, Sintilimab,Duvarizumab，Camrelizumab )and lenvatinib given at the
recommended dose in pediatric and young adolescent patients((5 year-oldPhase:
Phase 2/Phase 3